STAT1 and neoplasm: Importantly, the combination of YAP inhibitor with anti-PD-1 showed significant improvement on tumor suppression, independent of the STAT1-IRF1 axis and canonical ISGs, providing a new molecular circuit of IFN-γ-induced adaptive resistance to IOs that can be targeted to enhance ICB efficacy [117].